The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.
 
Vanessa Anne Eulo
No Relationships to Disclose
 
Breelyn A. Wilky
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - Adaptimmune; Daiichi Sankyo; Deciphera; SpringWorks Therapeutics
Research Funding - Agenus
Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera
 
Jingqin Luo
No Relationships to Disclose
 
Angela C. Hirbe
Consulting or Advisory Role - AstraZeneca; Intellisphere, LLC; SpringWorks Therapeutics
Travel, Accommodations, Expenses - SpringWorks Therapeutics
 
Mia C. Weiss
No Relationships to Disclose
 
Peter John Oppelt
Speakers' Bureau - Bristol Myers Squibb; Eisai; Merck
 
Sarah Abaricia
No Relationships to Disclose
 
Jacqui Toeniskoetter
No Relationships to Disclose
 
Tyler Ruff
No Relationships to Disclose
 
Robert G Maki
Consulting or Advisory Role - AADi; American Board of Internal Medicine (ABIM); Bayer; Deciphera; Karyopharm Therapeutics; Pfizer; TRACON Pharma
Research Funding - Daiichi (Inst); Presage Biosciences (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Springer and Wiley: Books for contributions I have made to the published texts; Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - Bayer; TRACON Pharma
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly